https://doi.org/10.4081/hmr.v3i3.571

High dose chemotherapy and autologous transplantation in anti-CD20 antibodies era: still a place?

Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
Published: June 12, 2009
Abstract Views: 167
PDF: 233
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

U Vitolo
support@pagepress.org
A Chiappella
B Botto
High dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) is recommended in young (<65 years) patients with diffuse large B-cell lymphoma (DLBCL) without a complete response (CR) after first line chemotherapy or in patients with chemosensitive DLBCL at relapse. According to Italian Society of Haematology guidelines and others, this approach, as first line treatment should be considered in young patients with an intermediate/high or high-risk according to the age-adjusted International Prognostic Index (aa-IPI) only in approved study protocols.1,2 So far, in the pre-rituximab era, no clear benefits were shown in such patients, and conflicting results were generated in randomized studies, with similar survival rates in patients receiving either first-line HDC and ASCT, or standard chemotherapy without rituximab.3-7

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Vitolo, U., Chiappella, A., & Botto, B. (2009). High dose chemotherapy and autologous transplantation in anti-CD20 antibodies era: still a place?. Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.571
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).